Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain

Years of clinical trials, scrutinized results, and a hoped-for (but not guaranteed) approval from the U.S. Food and Drug Administration are all part of the lifecycle. If clinical trials repeatedly fall short of expectations or an FDA approval fails to materialize, it can be money down the drain for shareholders. Fate Therapeutics (NASDAQ: FATE) is hoping for the latter result for its immunotherapy treatments of B-cell lymphoma -- cancer that forms in a person's white blood cells.